Â鶹ÊÓƵ aims to maximise the impact of its scientific discoveries; where appropriate this is achieved through commercialisation of its intellectual property rights. This primarily involves licensing new discoveries and technologies to pharma and biotech companies, but in some cases commercialisation is achieved through spinning-out new companies such as .
Using hPSCs as a source of human amnion-like cells provides a standardised, inexpensive and potentially unlimited source of amnion cells
This novel technology can simultaneously profile multiple histone modifications and transcriptomes, at single-cell resolution